PT-141

PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin-4 receptor agonist that acts centrally in the hypothalamus to increase sexual desire. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist and the first FDA-approved pharmacotherapy to target the central nervous system for sexual dysfunction. Approved in June 2019 under the brand name Vyleesi, it is indicated for hypoactive sexual desire disorder (HSDD) in premenopausal women — a condition characterized by low sexual desire causing marked distress that affects an estimated 10% of adult women in the United States. Unlike sildenafil, tadalafil, and other phosphodiesterase-5 inhibitors that act peripherally on vascular smooth muscle, PT-141 works upstream in the brain, modulating the neural circuits that govern motivation and desire rather than simply facilitating blood flow.

PT-141 was discovered serendipitously during research on Melanotan II (MT-II), a synthetic analog of α-melanocyte-stimulating hormone (α-MSH) originally developed as a sunless tanning agent. Researchers at the University of Arizona noted that MT-II produced spontaneous erections in male volunteers — an unexpected melanocortin effect. Subsequent medicinal chemistry work produced bremelanotide, a cyclic variant engineered to eliminate the prominent blood-pressure liability of MT-II while retaining its CNS-mediated pro-sexual activity. The cyclic structure confers resistance to peptidase degradation and enables subcutaneous delivery with roughly 100% bioavailability.

Clinically, PT-141 is administered as a 1.75 mg subcutaneous auto-injector approximately 45 minutes before anticipated sexual activity. Onset of desire-enhancing effects typically occurs within 30–60 minutes and lasts 6–12 hours, with a plasma half-life of approximately 2.7 hours. The RECONNECT Phase III trials demonstrated statistically significant improvements in satisfying sexual events and reductions in distress scores in premenopausal women with HSDD. In men, off-label use for erectile dysfunction — particularly in those who do not respond to PDE5 inhibitors — showed 62–67% response rates versus 21–33% for placebo in Phase II trials.

Beyond sexual function, melanocortin system engagement by PT-141 influences appetite, mood, and inflammation, reflecting the broad biological role of MC4R in energy homeostasis and autonomic regulation. The most common adverse effect is nausea (~40% incidence), attributable to MC4R activation in the dorsal motor nucleus of the vagus nerve; this typically diminishes with repeated dosing. A transient 2–6 mmHg increase in systolic blood pressure is also consistently observed, necessitating avoidance in patients with uncontrolled hypertension or cardiovascular disease.

PT-141 exerts its pro-sexual effects primarily by activating melanocortin-4 receptors (MC4R) in key hypothalamic nuclei, including the medial preoptic area (mPOA), the paraventricular nucleus (PVN), and the arcuate nucleus. MC4R is a Gs-coupled receptor; its activation elevates intracellular cAMP, which in the mPOA triggers downstream release of dopamine into the mesolimbic and nigrostriatal pathways. This dopaminergic surge is directly responsible for the motivational and desire-amplifying effects of PT-141 — paralleling how endogenous α-MSH participates in arousal states. This mechanism is entirely distinct from PDE5 inhibitors like sildenafil, which amplify nitric oxide–cGMP signaling in penile smooth muscle without engaging motivational circuitry.

MC4R knockout mouse studies have confirmed that MC4R is necessary for both the erectile and libido-enhancing effects of bremelanotide: animals lacking MC4R show no response to PT-141, establishing that this receptor is the functional target rather than an epiphenomenon. PT-141 also binds MC3R with lower affinity; MC3R modulation may contribute to anti-inflammatory signaling and to the complex appetite-suppression effects occasionally reported by users. The peptide does not meaningfully activate MC1R (tanning/pigmentation) or MC2R (ACTH/cortisol), which is why melanogenesis is far less pronounced with PT-141 than with its precursor Melanotan II.

Pharmacokintetically, PT-141 reaches peak plasma concentration (Cmax) approximately 1 hour after subcutaneous injection and has a terminal half-life of ~2.7 hours. It crosses the blood-brain barrier to achieve hypothalamic concentrations sufficient for receptor activation within 30–45 minutes post-injection. Nausea — the most prominent adverse effect — arises from MC4R activation in the dorsal motor nucleus of the vagus nerve, which controls gastric motility; this central vagal mechanism explains why antiemetics that act peripherally are less effective than those with CNS activity. The transient blood-pressure elevation observed in clinical trials (~2–6 mmHg systolic) reflects MC4R-mediated sympathetic activation and resolves within 12 hours.

The pivotal human evidence for PT-141 comes from the RECONNECT program — two identical, randomized, double-blind, placebo-controlled Phase III trials in 1,267 premenopausal women with HSDD (Clayton et al., Obstet Gynecol, 2019). The co-primary endpoints were change from baseline in the number of satisfying sexual events (SSEs) per month and change in the Female Sexual Distress Scale–Desire/Arousal/Orgasm (FSDS-DAO) item 13 score. PT-141 1.75 mg significantly outperformed placebo on both endpoints across both trials: SSEs increased by approximately 0.5–0.7 more events per month, and distress scores improved by ~1.0 more point. While the absolute effect sizes appear modest, they were consistent across 24-week treatment and statistically robust. Nausea was reported by 40.1% of PT-141 recipients versus 1.2% placebo; flushing by 20.4%; headache by 11.7%. A 52-week open-label extension (Simon et al., 2019) confirmed sustained efficacy with no evidence of tachyphylaxis and documented a reproducible but transient 2–6 mmHg systolic blood pressure rise resolving within 12 hours of each dose.

In men, the key Phase II data come from Diamond et al. (Int J Impot Res, 2004), a proof-of-concept study in which PT-141 was administered intranasally (the route later replaced by subcutaneous injection). In 62 men who had an inadequate response to sildenafil 100 mg, PT-141 0.4–1.2 mg produced clinically meaningful erectile responses (measured by RigiScan) in approximately 62% of subjects versus 21% placebo. In a broader cohort, response rates were 67% (PT-141) versus 33% (placebo). This finding positioned PT-141 as a potential second-line option for PDE5i non-responders — a population with limited alternatives — and drove significant off-label use in men despite no FDA approval for this indication.

Dose-finding for the approved women's dose was established in a Phase IIb dose-ranging study (Clayton et al., J Womens Health, 2016) evaluating 0.75, 1.25, and 1.75 mg subcutaneous doses. The 1.75 mg dose produced the best efficacy-to-tolerability ratio; lower doses were effective but numerically weaker, while higher doses were not tested. All doses produced statistically significant improvements in FSFI desire domain scores and FSDS distress scores versus placebo.

Mechanistic support from animal models is strong: MC4R knockout mice fail to show any erectile or arousal response to bremelanotide, confirming that MC4R is the obligate receptor. Wildtype mice treated with PT-141 show increases in dopamine overflow in the nucleus accumbens (measured by in vivo microdialysis), directly linking MC4R activation to mesolimbic dopaminergic output — the same circuit engaged by natural sexual stimuli.

The overall body of evidence supports PT-141 as a genuinely mechanistically novel treatment with consistent clinical signal, particularly for women with HSDD and men who fail standard PDE5 inhibition. The primary limitation for broader adoption is the nausea burden (~40%) and the blood pressure contraindication, which excludes hypertensive patients who are, paradoxically, among those most likely to seek alternatives to PDE5 inhibitors.[1][2][3][4]

Peptides commonly paired with PT-141 for synergistic effects.